Voyager Therapeutics, Inc. cotiza a 2.27 USD y tiene una capitalización bursátil de $140M. En los últimos 12 meses ha facturado $34M con un margen de flujo de caja libre del -334.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for t…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.40 | $-0.47 | $-0.47 |
| Estimado | $-0.44 | $-0.51 | $-0.53 | $-0.51 |
| Sorpresa | — | +21.6% | +11.3% | +7.8% |
| Métrica | VYGR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -326.6% | -38.6% | -287.9% |
| Net Margin | -296.5% | -33.6% | -263.0% |
| FCF Margin | -334.5% | -13.9% | -320.7% |
| ROE | -61.1% | -40.4% | -20.7% |
| ROA | -47.5% | -32.0% | -15.5% |
| Current Ratio | 7.64 | 2.84 | +4.80 |
| Debt / Equity | — | 0.28 | — |